The burden of productivity loss of U.S. commercially insured patients diagnosed with Dupuytren’s disease undergoing collagenase versus fasciectomy treatment

ABSTRACT

Background: We conducted a comparative assessment of the productivity loss associated with the two different treatment options for Dupuytren’s disease: collagenase and fasciectomy.

Methods: The retrospective claims analysis was performed using the data from IBM MarketScan® Commercial (CD) and Health and Productivity Management (HPM) Databases over five years (2012–2016). We identified two cohorts of patients who underwent either collagenase or fasciectomy in the CD. Propensity-score matched patients were linked to their productivity loss claims in the HPM database. Productivity loss measures were assessed over a 12-month follow-up period.

Results: Out of 702 collagenase and 999 fasciectomy propensity score-matched patients in the CD, there were 147 collagenase and 273 fasciectomy patients in the HPM database. Over the follow-up period, collagenase-treated patients were significantly less likely to use short-term disability (STD) leave (9.7% vs. 20.2%; P = 0.009), reflecting in the lower average number of absent STD days (mean, 2.8 vs. 8.1; P = 0.002) in comparison to fasciectomy-treated. The mean indirect STD cost was considerably lower in the collagenase vs. fasciectomy group ($375 vs. $1,108; P = 0.002).

Conclusion: This study indicates that collagenase vs. fasciectomy treatment may be related to a lower rate of workplace absence and lower indirect cost in a year following the treatment.

KEYWORDS:

• Collagenase
• Dupuytren’s disease
• fasciectomy
• indirect costs
• productivity loss

Acknowledgments

A part of the study findings has been previously presented at the 20th Annual Meeting of the American Association for Hand Surgery, in January 2020, Florida, U.S.

Declaration of interest

Djurdja Vukicevic, Vladimir Zah, Simona Tatovic and Martina Imro are employees of ZRx Outcomes Research, Inc. David Hurley is an employee of Endo Pharmaceuticals Inc. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Author contribution statement

VZ, DV, DH - Conceptualization of the study and design. VZ, MI, DH, ST – Analysis and interpretation of the data. VZ, ST, DH - Drafting of the paper. All authors revised critically for intellectual content, approved the version of the paper to be published and agree to be accountable for all aspects of the work.

Statement on ethical approval

The IBM MarketScan® databases comply with the Health Insurance Portability and Accountability Act (HIPAA) of 1996, protecting the privacy and ensuring the confidentiality of personal data. As the database records are fully de-identified, the study was thus exempt from review and ethical approval by an institutional review board.

Statement on patient consent

The database records are fully de-identified; hence patient consent was not needed.

Supplementary material

Supplemental data for this article can be accessed here.

Additional information

Funding

Funding for this analysis was provided by Endo Pharmaceuticals Inc.